

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS**

DePuy Mitek, Inc.  
a Massachusetts Corporation

Plaintiff,

v.

Arthrex, Inc.  
a Delaware Corporation, *et al.*

Defendants.

Civil Action No. 04-12457 PBS

**DEFENDANTS ARTHREX, INC.'S AND PEARSALLS, LTD.'S RESPONSE TO DEPUY  
MITEK'S BENCH MEMORANDUM RELATING TO PRE-SUIT TESTING**

Dated: August 10, 2007

Charles W. Saber  
Stephen A. Soffen  
Salvatore P. Tamburo  
DICKSTEIN SHAPIRO LLP  
1825 Eye Street, N.W.  
Washington, D.C. 20006-5403  
Telephone: (202) 420-3116  
Facsimile: (202) 420-2201

Christopher Weld, Jr. (BBO # 522230)  
Raymond P. Ausrotas (BBO # 640315)  
TODD & WELD LLP  
28 State Street, 31st Floor  
Boston, MA 02109  
Telephone: (617) 720-2626  
Facsimile: (617) 227-5777

Counsel for Defendants  
Arthrex, Inc. and Pearsalls Ltd.

Defendants Arthrex, Inc. and Pearsalls, Ltd. (collectively “Arthrex”) submit this paper in response to the bench memorandum relating to pre-suit testing filed by DePuy Mitek on August 3, 2007.

This Court has already stated the fact that DePuy Mitek conducted tests is not privileged information. Yet, DePuy Mitek continues to argue that Arthrex should not be permitted to refer to this *admissible* evidence, blithely contradicting this Court’s prior pronouncement. As explained below, the fact that DePuy Mitek conducted tests is *not* privileged information. To the extent any question exists as to whether this information is privileged -- which there is none -- DePuy Mitek waived its claim of privilege. Further, DePuy Mitek’s reliance on *McKesson Info. Solutions, Inc. v. Bridge Med., Inc.*, 434 F. Supp. 2d. 810 (E.D. Cal. 2006) is entirely misplaced. *McKesson* merely precludes evidence pertaining to the assertion of privilege, something Arthrex has already agreed not to introduce.

DePuy Mitek raised this issue in its second motion *in limine* and this Court responded that “it’s not protected that you conducted tests, and that can come out.” Ex. 1 at 27:23-24. The fact that DePuy Mitek conducted tests is *not* privileged information. Simply because DePuy Mitek believes “there will necessarily be an implicit adverse inference that the test results were unfavorable to Mitek” does not warrant the preclusion of otherwise *relevant and admissible* evidence. DePuy Mitek cites no law for the proposition that *relevant and admissible* evidence should be precluded simply because it is unfavorable to a party.

The fact that DePuy Mitek did tests, as this Court has repeatedly noted, is simply not privileged information. But even if DePuy Mitek had a colorable argument that the fact it conducted tests is privileged -- which they do not -- that argument was waived. DePuy Mitek has produced documents indicating that it conducted tests. Ex. 2 at 2d; Ex. 3 at 2b. DePuy

Mitek has likewise permitted testimony relating to these tests.<sup>1</sup> Ex. 4 at 58:6-59:2; 59:15-70:22.

DePuy Mitek cannot now claim that the fact that it conducted tests is privileged.

Furthermore, DePuy Mitek woefully overstates the facts and the holding of *McKesson*.<sup>2</sup> The *McKesson* court held that the plaintiff was “precluded, in all respects, from introducing evidence or testimony *pertaining to Bridge’s assertion of the attorney client privilege* over the opinion of counsel it received....” *Id.* at 812 (emphasis added). This Court has already stated that the results of the tests are likely privileged and instructed Arthrex’s Counsel not to argue the assertion of privilege to the jury. Ex. 1 at 28:6-13. *McKesson* does nothing more than restate the demarcation that this Court has already expressed.

For the foregoing reasons and the reasons in Arthrex’s response to DePuy Mitek’s motion *in limine* no. 2, Arthrex should not be precluded from submitting any evidence or making any argument to the jury about the existence of DePuy Mitek’s pre-suit testing.

---

<sup>1</sup> Such testimony regarding the pre-suit testing conducted by DePuy Mitek is the only remaining issue to be resolved on the deposition designation objections. Should the Court maintain its position that the fact that the tests were conducted is not privileged this remaining dispute should, likewise, be resolved.

<sup>2</sup> It is questionable if *McKesson*, a case regarding an opinion of counsel relating to patent infringement, even applies to this case where privilege is being asserted to protect the fact that tests were conducted.

Dated: August 10, 2007

Respectfully submitted,

By: /s/Charles W. Saber

Charles W. Saber

Stephen A. Soffen

Salvatore P. Tamburo

DICKSTEIN SHAPIRO LLP

1825 Eye Street, N.W.

Washington, D.C. 20006-5403

Telephone: (202) 420-3116

Facsimile: (202) 420-2201

Christopher Weld, Jr. (BBO # 522230)

Raymond P. Ausrotas (BBO # 640315)

TODD & WELD LLP

28 State Street, 31st Floor

Boston, MA 02109

Telephone: (617) 720-2626

Facsimile: (617) 227-5777

Counsel for Defendants

Arthrex, Inc. and Pearsalls Ltd.

**CERTIFICATE OF SERVICE**

I HEREBY CERTIFY that a true and correct copy of the foregoing DEFENDANTS ARTHREX, INC.'S AND PEARSALLS LTD.'S RESPONSE TO DEPUY MITEK'S BENCH MEMORANDUM RELATING TO PRE-SUIT TESTING was served, via the Court's email notification system on the following counsel for Plaintiff on the 10th day of August 2007:

Lynn A. Malinoski  
Woodcock Washburn, LLP  
Cira Centre, 12th Floor  
2929 Arch Street  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

Daniel J. Gleason  
Nutter McClennan & Fish LLP  
World Trade Center West  
155 Seaport Boulevard  
Boston, MA 02210-2604  
Telephone: (617) 439-2000  
Facsimile: (617) 310-9000

/s/Charles W. Saber

# **Exhibit 1**

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS

DePUY MITEK, INC., )  
a Massachusetts Corporation, )  
Plaintiff )  
 )  
-VS- ) CA No. 04-12457-PBS  
 ) Pages 1 - 37  
ARTHREX, INC., )  
a Delaware Corporation, )  
and Pearsalls Ltd., )  
a Private Limited Company )  
of the United Kingdom, )  
Defendants )

FINAL PRETRIAL CONFERENCE

BEFORE THE HONORABLE PATTI B. SARIS  
UNITED STATES DISTRICT JUDGE

A P P E A R A N C E S:

DIANNE B. ELDERKIN, ESQ., MICHAEL J. BONELLA, ESQ.,  
LYNN A. MALINOSKI, ESQ., and ANGELA VERRECCHIO, ESQ.,  
Woodcock Washburn, LLP, Cira Centre, 12th Floor,  
2929 Arch Street, Philadelphia, Pennsylvania, 19104-2891,  
for the Plaintiff.

CHARLES W. SABER, ESQ. and SALVATORE P. TAMBURO, ESQ.,  
Dickstein Shapiro, LLP, 1825 Eye Street, N.W., Washington,  
D.C., 20006-5403, for the Defendants.

United States District Court  
1 Courthouse Way, Courtroom 19  
Boston, Massachusetts  
July 31, 2007, 4:00 p.m.

LEE A. MARZILLI  
OFFICIAL COURT REPORTER  
United States District Court  
1 Courthouse Way, Room 3205  
Boston, MA 02210  
(617) 345-6787

Page 26

1 privilege, as I understand it --

2 MR. SABER: Or work product, the same thing, your  
3 Honor.

4 THE COURT: -- protection under the work product  
5 doctrine. And it's just I don't know if it is or not. It's  
6 quite clear that if a lawyer hires a private eye to go out  
7 and take witness statements, that those are protected under  
8 the work product doctrine, and you have to make certain  
9 showings to get them. It's also clear you can't draw an  
10 adverse inference if it's a fair application of a work  
11 product doctrine. That's clear Federal Circuit law. Is this  
12 the fair assertion of the work product doctrine? Have either  
13 of you found a case on this?

14 MR. SABER: Yes, your Honor. I think we cited four  
15 cases to you.

16 THE COURT: Not directly on this.

17 MR. SABER: Well, two of them were exactly on  
18 point.

19 THE COURT: Which are the two that you say are  
20 directly on point?

21 MR. SABER: I don't have the names, but they're the  
22 first two that we cited, your Honor.

23 THE COURT: The first two?

24 MR. SABER: Yes.

25 THE COURT: Say what, that you can get what?

Page 27

1 MR. SABER: That there's no privilege for -- these  
2 were both cases about test results done by the plaintiff in a  
3 case.

4 THE COURT: Well, by the plaintiff, that's one  
5 thing, but what if --

6 MR. SABER: That's what this is.

7 MS. VERRECCHIO: Your Honor, those tests were not  
8 conducted at the request of counsel. And in this case,  
9 in-house counsel for DePuy Mitek and outside litigation  
10 counsel directed the tests to be done before the suit was  
11 filed and in anticipation of litigation, so it's clearly work  
12 product.

13 THE COURT: I'm just saying, we're two days before  
14 trial. I don't know what the answer is. No one should argue  
15 it in their opening. We did not find a case directly -- your  
16 cases were not where they were directed by an attorney in  
17 anticipation of litigation. On the other hand, we found a  
18 case that said that the fact that there were tests was not  
19 protected -- that's why it's not so straightforward -- the  
20 fact that there are tests, but the results of the test may  
21 well be protected. But, you know, just like an investigator  
22 has to disclose whom he interviewed but maybe not what the  
23 statement was. So I think it's not protected that you  
24 conducted tests, and that can come out. But you can't ask  
25 for an instruction on an adverse inference if in fact that

Page 28

1 they were protected or argue they should have been produced  
2 because I think there's some argument that that is  
3 protected. They're pretty fine lines that we're walking  
4 here, and I am not prepared to rule right now, and no one  
5 should argue any adverse inference in their opening  
6 statements. You can argue that "You won't see any tests,"  
7 because the absence of evidence is a strong thing in your  
8 quiver because you do have tests, but that's different from  
9 saying, "The lawyers ordered tests, and they won't produce  
10 them," because I think there's at least a good shot that they  
11 are protected, the actual results.

12 MR. SABER: Okay, well, I won't make that argument,  
13 your Honor.

14 THE COURT: None of these want to be an appeal  
15 issue. You don't want to draw -- unless you've got a slam  
16 dunk about it, permitting an adverse inference on a test  
17 conducted under the auspices of a lawyer in anticipation of  
18 litigation are too close to the line, so we don't want that  
19 appeal issue.

20 So then what are the other issues that we have?

21 MS. ELDERKIN: Your Honor, we had some issues come  
22 up with Dr. Gitis' supplemental report. This was not raised  
23 in the motions in limine because his deposition didn't happen  
24 until last week. I'll let Mr. Bonella --

25 THE COURT: If it's not a motion in limine, I'm not

Page 29

1 dealing with it, okay. I have a room upstairs full. What  
2 are the other motions in limine?

3 MR. TAMBURRO: Your Honor, we filed a motion in  
4 limine on a new argument that DePuy Mitek made for the first  
5 time late in this case regarding the minimal impact of  
6 coating, and --

7 THE COURT: I read that, and that's overruled.  
8 That's what their whole argument has been all along.

9 MR. TAMBURRO: Well, actually, it's not quite right,  
10 your Honor. They've been arguing all along that the coating  
11 does not prevent certain things from happening in the  
12 suture. This is a new argument they're making, and they're  
13 citing Dr. Brookstein to support it, but he never made these  
14 arguments.

15 THE COURT: That's overruled. Yes, he did. I  
16 mean, that was the whole gist of this thing, that it doesn't  
17 matter, and it's just a tiny amount of coating, and it's  
18 de minimis and insignificant. That's what this case is  
19 about. Both of you are trying to get me to direct the case,  
20 and I'm not going to do it.

21 What's the next motion in limine?

22 MS. MALINOSKI: We had filed a motion that was  
23 directed to Arthrex trying to introduce evidence about the  
24 development of the Orthocord product and the reasons that  
25 Mitek developed it. Orthocord is a suture that DePuy Mitek



# **Exhibit 2**

Katie's Current Projects 6/29/04

1. Project MoniTorr – CPC representative
  - a. Recently completed Design Verification completion reports for Cost Reduction project for Cartridge top and meatus cone changes.
  - b. Regularly attended weekly Cost Reduction meetings to keep up-to-date on progress.
  - c. One more cost reduction project in process (catheter change). Will likely require design verification testing.
  - d. Collaborated with Ziad Mohamed (cost reduction project leader), Sharon Shantz, and MoniTorr members from AVAIL medical.
2. Project Orthocord, Violet - CPC representative
  - a. Working with MITEK project leader, Jonathan Howe, to gather information for Marketing. White papers have been written by MITEK which included data gathered here in CPC.
  - b. Working with J/H and Dan Burkley to gather SEM pictures for MITEK marketing of violet Orthocord and competitor, Fiberwire.
  - c. Completed summary report memos of possible competitors to Orthocord, including MaxBraid and Arthrex Bio-Fastak and Corkscrew sutures.
  - d. 

REDACTED DUE TO  
ATTORNEY-CLIENT OR WORK  
PRODUCT PRIVILEGE



Coated and Uncoated Fiberwire was sent to test for straight tensile and bending rigidity as per a patent. Composition, SEM and denier analysis were needed to verify the coated and uncoated samples were the same. Bending rigidity was done in the patent using a Kawabata Bend tester. Tried to understand and learn how to use the tester in Ilya's lab.

  - e. 

REDACTED DUE TO  
ATTORNEY-CLIENT OR WORK  
PRODUCT PRIVILEGE
  - f. Finalizing technical reports for violet ORTHCORD design verification and stability study.
  - g. PQ is on-going in San Angelo.
  - h. The second stability study for Orthocord violet is being developed. Les and I met to finalize the protocol. This protocol will test for 2X EO sterilization.
3. Project Orthocord, Blue – CPC representative
  - a. Spoke to Michael Pelekis to get ETHICON biocompatibility recommendations for Orthocord blue. MITEK has previous biocompatibility studies on D&C blue #6 for anchors. Michael and I are going to research biocompatibility studies for PDS blue. If enough information exists, it is ETHICON's recommendation that no new biocompatibility studies are needed.
  - b. Orthocord blue was brought to the stability study committee on 6/10/04. It was the stability committee's recommendation to initiate an off-critical path study to verify stability of the suture with the blue dye out to 5 years.
  - c. Currently working on revising the CPC Orthocord Blue plan. I would like to set up a CPC project review meeting soon.

CONFIDENTIAL- OUTSIDE  
ATTORNEYS EYES ONLYDePuy Mitek, Inc v. Arthrex, Inc  
C.A. No04-12457 PBS

DMI039571



- d. Development samples of Orthocord blue are being made.
- e. Met with Enilma Miller to discuss using the violet TM's for blue. Most of them will not have to be updated. We would like to verify with the more development data.

4. LIMS

- a. Completed Agilent CSV 1<sup>st</sup> completion report. Qiang ran protocol a 2<sup>nd</sup> time successfully.
- b. The 2<sup>nd</sup> Agilent CSV completion report is written, awaiting signatures. The only items left are the SMP (which may need some testing) and the relevant SOPs.
- c. I have finalized the Waters SRS and have routed it for approval in ECCS.
- d. Waters IQ/OQ/PV was completed. Once I receive the paperwork, we can move into developing the tracematrix and any subsequent protocol and test scripts.
- e. Participated in Value Stream Mapping process with LIMS project team and Jim Pastore to create current state map of CPC processes.

5. Part 11/CSV

- a. I worked with Mark Storch to determine if there is any money in the R&D budget to bring in vendor to work on the remedial CSV of several pieces of equipment (including the Instron software, viscometer, titrator, NMR and x-ray Diffractometer.) Mark said there was capital money available. I worked with Mark and Darrie Christmas to determine if CSV would be capital or expense. With input from Phyllis Woodford and Jean Carbone, it was determined that it was.
- b. I have called Stelex to obtain a quote for the remedial CSV work on equipment previously mentioned. Currently working on putting together the information Stelex need to create their quote.
- c. I have worked with Robin Ragland and Josh Samon about obtaining quotes for software upgrades to the viscometer and x-ray Diffractometer. These upgrades would have to be done before the remedial CSV work. I spoke to the sales representative to the x-ray Diffractometer to clarify quote and have received new quote from Viscotek for the viscometer.
- d. I spoke to Jack Zhou about the Part 11/CSV plans. He felt the Instron Series IX software could be done in-house. For the x-ray Diffractometer, due to the time needed by the vendors to learn the equipment to do the CSV, it may take less time for Josh to do the CSV himself, then to spend time teaching the vendors about the equipment. I need to talk to Josh about this issue. Jack Zhou has also obtained a quote from Nugensis for them to perform the CSV – not to be done in-house.
- e. I attended a conference call with Part 11 leaders in the field concerning new issues around Part 11.

6. Barbed Suture

- a. There are no new updates on the Belle project.

7. Calibration

- a. Still trying to get onto the Pilgrim system. There have been many software related problems with my access. I have been working with Pat Raics to gain access.
- b. Once I get on the system, inventory of all the equipment in CPC can roll out.

CONFIDENTIAL- OUTSIDE  
ATTORNEYS EYES ONLY

DePuy Mitek, Inc v. Arthrex, Inc  
C.A. No04-12457 PBS

DMI039572

- c. Analytical chemistry has already begun their inventory with help from Robin Larkin and May Xu.
- 8. Mulberry
  - a. Samples will be here this week to start stability study. I will be working with Claudia to complete the baseline testing.

**CONFIDENTIAL- OUTSIDE  
ATTORNEYS EYES ONLY**

*DePuy Mitek, Inc v. Arthrex, Inc*  
*C.A. No04-12457 PBS*  
**DMI039573**

# **Exhibit 3**

Katie's Current Projects 7/26/04



1. Project MoniTorr – CPC representative
  - a. Regularly attended weekly Cost Reduction meetings to keep up-to-date on progress.
  - b. Met to discuss requirement matrix for 3<sup>rd</sup> cost reduction project – catheter change. Design Verification testing including CMG flow rate, pressure accuracy, catheter diameter, catheter length and tube length will need to be done.
  - c. Started this Design Verification Protocol
  - d. Collaborated with Hannah Davies (cost reduction project leader), Sharon Shantz, and MoniTorr members from AVAIL medical.
2. Project Orthocord, Violet - CPC representative
  - a. Working with MITEK project leader, Jonathan Howe, to gather information for Marketing. White papers have been written by MITEK which included data gathered here in CPC.
  - b. 

REDACTED DUE TO  
ATTORNEY-CLIENT OR WORK  
PRODUCT PRIVILEGE

Tested coated and uncoated Fiberwire for straight tensile and bending stiffness. Mitek would now like to remove the coating from finished goods Fiberwire and test again.
  - c. Finalized technical reports for violet ORTHCORD design verification, stability study and other studies.
  - d. Orthocord violet launched for non-needed product. Investigation is on-going for needed product failure in OQ.
  - e. The second stability study for Orthocord violet is being developed. Should sing off on the protocol this week. This protocol will test for 2X EO sterilization.
3. Project Orthocord, Blue – CPC representative
  - a. CPC project review meeting set up for next week.
  - b. Development/Coating samples in sterilization. I should have them today.
  - c. Met with Enilma Miller, Ilya Koyfinan, Don Hill to discuss Orthocord blue development testing plan.
4. LIMS
  - a. Waters SRS approved in ECCS.
  - b. Started Waters traceability matrix.
  - c. Started the Instron Series IX SRS.
  - d. Met with several CPC associates (Christophe, Liz, Chris, Hwason, Debi) to explain and discuss filling out data gathering survey for LIMS.
  - e. Filled out survey.
5. Part 11/CSV
  - a. Worked with Stelex to put together quote for remedial CSV. Put together CAR for the work. Awaiting response.
  - b. I have obtained software upgrade quotes for x-ray Diffractometer and Viscometer. I am going to meet with Jack to put in PO's. Once they complete the upgrades, Stelex can come in and start the CSV.

CONFIDENTIAL- OUTSIDE  
ATTORNEYS EYES ONLY

DePuy Mitek, Inc v. Arthrex, Inc  
C.A. No04-12457 PBS  
DMI039560



- c. I attended John Sheets' staff meeting to give an update on Part 11. JS wanted assessments done of all of R&D. I am going to coordinate this assessment. Meeting with Mark and Jack this Friday to discuss.
- d. Attended a meeting with Kathye Concannon, Robin Larkin, Rich Hutchinson, Len Chiu concerning a Honeywell monitoring system they might purchase for LAR.
- 6. Barbed Suture
  - a. Belle is now the Barbed suture project. Met with Nick Popadiuk to test a few in-house produced samples.
  - b. Met with Nick, Brian Lisa and others to discuss the relationship matrix.
- 7. Calibration
  - a. Started the inventory listing. I put together the lists that the Calibration dept. has of CPC equipment and sent out to the group. I have asked that everyone do any inventory and get back to me.
  - b. I will be compiling the lists and setting up meetings to discuss new equipment.
- 8. Mulberry
  - a. Completed baseline stability study testing with Claudia on TVT-O.

**CONFIDENTIAL- OUTSIDE  
ATTORNEYS EYES ONLY**

*DePuy Mitek, Inc v. Arthrex, Inc*  
*C.A. No04-12457 PBS*  
**DMI039561**

# **Exhibit 4**



30(b)(6) Deposition of:  
Katherine Seppa

February 10, 2006

Page 1

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

C.A. No. 04-12457 PBS

-----X  
DePUY MITEK, INC.,

A Massachusetts Corporation,

Plaintiff,

v.

ARTHREX INC.,

A Delaware Corporation,

Defendants.  
-----X

**TRAVEL  
TRANSCRIPT**

30(b)(6) DEPOSITION OF KATHERINE SEPPA

Somerset, New Jersey

February 10, 2006

Reported by:

MARY F. BOWMAN, RPR, CRR

JOB NO.: SE 226

30(b)(6) Deposition of:  
Katherine Seppa

February 10, 2006

<p style="text-align: right;">Page 58</p> <p>1 SEPPA</p> <p>2 validation of the subjective handling wet dry tie</p> <p>3 down version 2.</p> <p>4 <b>Q. This is version 2?</b></p> <p>5 A. Yes.</p> <p>6 <b>Q. Let me show you what has previously</b></p> <p>7 <b>been marked as Defendant's Exhibit 30. I am going</b></p> <p>8 <b>to ask if you are familiar with that?</b></p> <p>9 A. Yes.</p> <p>10 <b>Q. What is this?</b></p> <p>11 A. This is a list of my projects that I</p> <p>12 have been working on.</p> <p>13 <b>Q. You are the Katie?</b></p> <p>14 A. Yes.</p> <p>15 <b>Q. And this is -- is this something you</b></p> <p>16 <b>do regularly, list, do a current projects list?</b></p> <p>17 A. I wouldn't say regularly but</p> <p>18 occasionally.</p> <p>19 <b>Q. I want to ask you about a couple of</b></p> <p>20 <b>things on here, if I could. Number one, project</b></p> <p>21 <b>Orthocord, violet item C completed report, members</b></p> <p>22 <b>and possible competitors to Orthocord, including</b></p> <p>23 <b>Max Braid, Arthrex, BioFastrak and Corkscrew</b></p> <p>24 <b>sutures. Do you know what that is referring to?</b></p> <p>25 A. There was competitive testing that we</p>	<p style="text-align: right;">Page 60</p> <p>1 SEPPA</p> <p>2 <b>patent, do you know what that means?</b></p> <p>3 A. It meant that those two --</p> <p>4 MR. FALKE: Wait. I am going to</p> <p>5 caution you not to disclose the substance of</p> <p>6 communications you might have had with</p> <p>7 counsel. If you can answer the question</p> <p>8 without revealing the substance of those</p> <p>9 communications, then you can answer the</p> <p>10 question. If you can answer the question</p> <p>11 without revealing that substance, you can</p> <p>12 answer the question. But if you can't</p> <p>13 answer the question without revealing that,</p> <p>14 then I am going to ask you not to answer the</p> <p>15 question.</p> <p>16 A. Can you repeat the question?</p> <p>17 (Record read)</p> <p>18 MR. FALKE: You can answer that yes,</p> <p>19 no or I don't know.</p> <p>20 A. I don't remember. I don't remember.</p> <p>21 <b>Q. But did you do a bending rigidity test</b></p> <p>22 <b>on the coated and uncoated Fiber Wire?</b></p> <p>23 MR. FALKE: Objection, asked and</p> <p>24 answered.</p> <p>25 A. I can't answer?</p>
<p style="text-align: right;">Page 59</p> <p>1 SEPPA</p> <p>2 did on those particular three sutures.</p> <p>3 <b>Q. What is Max Braid?</b></p> <p>4 A. I don't remember.</p> <p>5 <b>Q. Do you know what testing you did on</b></p> <p>6 <b>the Max Braid?</b></p> <p>7 A. I don't remember.</p> <p>8 MR. FALKE: Objection, outside the</p> <p>9 scope.</p> <p>10 <b>Q. Do you know what testing you did on</b></p> <p>11 <b>the Arthrex BioFastrak?</b></p> <p>12 A. I don't remember.</p> <p>13 <b>Q. Or the Corkscrew sutures?</b></p> <p>14 A. I don't remember.</p> <p>15 <b>Q. Item D, and part of that has been</b></p> <p>16 <b>redacted, "coated and uncoated Fiber Wire was sent</b></p> <p>17 <b>for straight tensile and bending rigidity as per</b></p> <p>18 <b>patent."</b></p> <p>19 <b>Do you see that?</b></p> <p>20 A. Yes.</p> <p>21 <b>Q. Did you perform or supervise tests of</b></p> <p>22 <b>coated and uncoated Fiber Wire for straight</b></p> <p>23 <b>tensile and bending rigidity?</b></p> <p>24 A. Yes.</p> <p>25 <b>Q. When it says bending rigidity as per</b></p>	<p style="text-align: right;">Page 61</p> <p>1 SEPPA</p> <p>2 MR. FALKE: It was asked and answered.</p> <p>3 <b>Q. No, you can answer that question. It</b></p> <p>4 <b>is a slightly different question than I asked</b></p> <p>5 <b>before. That's an example of where your counsel</b></p> <p>6 <b>objected, and you should go ahead and answer the</b></p> <p>7 <b>question.</b></p> <p>8 (Record read)</p> <p>9 A. Yes.</p> <p>10 <b>Q. Now, it says bending rigidity -- how</b></p> <p>11 <b>many times did you do that test, bending rigidity</b></p> <p>12 <b>test on the coated, uncoated Fiber Wire?</b></p> <p>13 A. I don't remember.</p> <p>14 <b>Q. Now, it says further on this that</b></p> <p>15 <b>paragraph, bending rigidity was done in the patent</b></p> <p>16 <b>using a kawabata bend tester. Do you see that?</b></p> <p>17 A. Yes.</p> <p>18 <b>Q. Remember we had some discussion</b></p> <p>19 <b>earlier today about the Kawabata bend tester? Did</b></p> <p>20 <b>you actually use the Kawabata bend tester to do</b></p> <p>21 <b>the bending rigidity test?</b></p> <p>22 A. No.</p> <p>23 <b>Q. What equipment did you use to do the</b></p> <p>24 <b>bending rigidity test? What equipment did you</b></p> <p>25 <b>use?</b></p>

16 (Pages 58 to 61)

30(b)(6) Deposition of:  
Katherine Seppa

February 10, 2006

Page 62

1 **SEPPA**  
2 A. The Instron, the bending stiffness.  
3 **Q. You did it on the Instron test?**  
4 A. Yes.  
5 **Q. Why didn't do you do it on the**  
6 **Kawabata bend tester?**  
7 MR. FALKE: I am going to caution the  
8 witness not to disclose the substance of any  
9 communications you had with counsel. You  
10 can answer the question if your answer will  
11 not reveal the substance of those  
12 communications, or if you don't know, then  
13 you can say you don't know.  
14 A. I don't know.  
15 **Q. What were the results of the test on**  
16 **the coated and uncoated Fiber Wire?**  
17 MR. FALKE: Again, I will caution you  
18 not to disclose the substance of any  
19 privileged communication you had with  
20 counsel. If you can answer the question  
21 without revealing that privilege, then you  
22 can answer the question. But if you can't,  
23 I will ask you not to answer the question.  
24 A. I can't answer.  
25 **Q. You can't answer because of the**

Page 63

1 **SEPPA**  
2 **instruction that he gave you?**  
3 A. Yes.  
4 MR. FALKE: Can you repeat the  
5 question?  
6 A. Was it what were the results?  
7 **Q. Yes, sir.**  
8 MR. FALKE: If you don't know the  
9 answer, you can say you don't know. If you  
10 know the answer, you can answer only if  
11 answering will not reveal the substance.  
12 A. I don't remember.  
13 **Q. You don't remember the results. Do**  
14 **you recall whether the one -- whether the coated**  
15 **and uncoated gave different numbers?**  
16 A. I don't remember.  
17 **Q. You said you don't remember if the**  
18 **numbers were the same or numbers were different?**  
19 A. I don't remember the results.  
20 **Q. Were the results put in written form?**  
21 A. Yes.  
22 **Q. And what did you do with the written?**  
23 **Did you make a report of the results?**  
24 A. Yes.  
25 **Q. And to whom did you give the report?**

Page 64

1 **SEPPA**  
2 MR. FALKE: I am going to caution you  
3 not to disclose the substance of  
4 communications with counsel. If you can  
5 answer the question without revealing the  
6 substance, you can answer. But if in  
7 answering the question you will reveal the  
8 substance of the communication, then I am  
9 going to instruct you not to answer.  
10 A. I can't answer.  
11 **Q. Again, I want to make sure is it**  
12 **because you don't remember the answer?**  
13 A. On the advice of my counsel.  
14 **Q. Because my only -- Eric, my only**  
15 **question is who did she give the report to?**  
16 MR. FALKE: Right. I understand, but  
17 I think the answer would reveal what the  
18 substance of the communication was. Right?  
19 MR. SABER: I don't think so but --  
20 MR. FALKE: I am going to stand.  
21 **Q. This also refers to a straight tensile**  
22 **test. Did you do a straight tensile test on the**  
23 **coated and uncoated Fiber Wire?**  
24 A. Yes.  
25 **Q. And what were the results of those**

Page 65

1 **SEPPA**  
2 **tests?**  
3 A. I don't remember.  
4 **Q. Do you remember whether you got the**  
5 **same result for the coated and uncoated or whether**  
6 **you got different results?**  
7 A. I don't remember.  
8 **Q. Were those results also put into**  
9 **writing?**  
10 A. Yes.  
11 **Q. And who did you give that report to?**  
12 MR. FALKE: I will give you the same  
13 instruction as before.  
14 A. I can't answer on the advice of my  
15 counsel.  
16 **Q. Let me show you what has previously**  
17 **been marked Defendant's Exhibit 31, and I ask if**  
18 **you can identify this?**  
19 A. Again, it is a list of my current  
20 projects.  
21 MR. FALKE: Hold on one second.  
22 Why don't you reask those two  
23 questions I told her not to answer, and she  
24 can answer them.  
25

17 (Pages 62 to 65)

30(b)(6) Deposition of:  
Katherine Seppa

February 10, 2006

<p style="text-align: right;">Page 66</p> <p>1 SEPPA</p> <p>2 BY MR. SABER:</p> <p>3 Q. On the record. The results of the</p> <p>4 coated and uncoated Fiber Wire, the bending</p> <p>5 rigidity test, who did you give those to?</p> <p>6 A. Rich Skula.</p> <p>7 Q. Straight tensile test between coated</p> <p>8 and uncoated test, who did you give that report</p> <p>9 to?</p> <p>10 A. Rich Skula.</p> <p>11 Q. Let's go to Defendant's Exhibit 31.</p> <p>12 And I think this is another one of those Katie</p> <p>13 current project reports. I want to ask about item</p> <p>14 2B, tested uncoated, coated and uncoated for</p> <p>15 straight tensile and bending stiffness. Does that</p> <p>16 refer to same tests referred to in Defendant's</p> <p>17 Exhibit 130?</p> <p>18 A. I don't know.</p> <p>19 Q. You don't know if these are additional</p> <p>20 tests, or whether these are referring to the same</p> <p>21 test?</p> <p>22 MR. FALKE: Objection, asked and</p> <p>23 answered.</p> <p>24 A. I don't know.</p> <p>25 Q. I may have asked you this, Ms. Seppa,</p>	<p style="text-align: right;">Page 68</p> <p>1 SEPPA</p> <p>2 Q. Was a further test done of uncoated</p> <p>3 Fiber Wire versus coated Fiber Wire?</p> <p>4 MR. FALKE: Object to the form.</p> <p>5 Outside the scope of the notice.</p> <p>6 A. Could you clarify the question?</p> <p>7 Q. Yes. Was a further test done on</p> <p>8 coated, uncoated Fiber Wire for doing -- was a</p> <p>9 further bending rigidity test done after</p> <p>10 Defendant's Exhibit 31 between coated and uncoated</p> <p>11 Fiber Wire?</p> <p>12 A. Yes.</p> <p>13 MR. FALKE: Object, outside the scope.</p> <p>14 You can answer.</p> <p>15 A. Yes.</p> <p>16 Q. And did you supervise that test? Did</p> <p>17 you do that test?</p> <p>18 A. I performed that test.</p> <p>19 Q. Was that using the same equipment as</p> <p>20 the earlier test?</p> <p>21 A. Yes.</p> <p>22 Q. And what were the results of that</p> <p>23 test?</p> <p>24 A. I don't know. I don't remember.</p> <p>25 Q. Do you know whether one scored higher</p>
<p style="text-align: right;">Page 67</p> <p>1 SEPPA</p> <p>2 and I apologize if I did. But do you recall</p> <p>3 whether you did more than one series of tests,</p> <p>4 bending rigidity test or straight testing test?</p> <p>5 MR. FALKE: Objection, asked and</p> <p>6 answered.</p> <p>7 A. I said I didn't know.</p> <p>8 Q. Does showing you documents refresh</p> <p>9 your recollection at all of that question?</p> <p>10 A. No.</p> <p>11 Q. Now, next sentence, Mitek would like</p> <p>12 now to remove the coating from the finished goods</p> <p>13 Fiber Wire and test again.</p> <p>14 Did that happen?</p> <p>15 A. Yes.</p> <p>16 Q. That the coating was removed from</p> <p>17 finished fiber wires and tested again?</p> <p>18 Was the coating removed -- was coating</p> <p>19 removed from finished good Fiber Wire?</p> <p>20 MR. FALKE: Do you need to take a</p> <p>21 break?</p> <p>22 THE WITNESS: Yes.</p> <p>23 (Recess)</p> <p>24 (Record read)</p> <p>25 A. I don't know.</p>	<p style="text-align: right;">Page 69</p> <p>1 SEPPA</p> <p>2 than the other?</p> <p>3 A. I don't remember.</p> <p>4 Q. Did you make a written report of that</p> <p>5 test?</p> <p>6 A. I don't remember.</p> <p>7 Q. I take it you wouldn't remember if you</p> <p>8 made it a report if you gave it to anybody?</p> <p>9 A. I don't remember.</p> <p>10 Q. Do you know why Mitek wanted to have</p> <p>11 the coating removed from the finished goods Fiber</p> <p>12 Wire tested again?</p> <p>13 MR. FALKE: Yeah. I am going to</p> <p>14 instruct you not to answer that question</p> <p>15 based on attorney work product.</p> <p>16 MR. SABER: That one I only asked if</p> <p>17 she knows.</p> <p>18 MR. FALKE: You can answer yes, no or</p> <p>19 I don't know.</p> <p>20 A. Yes.</p> <p>21 Q. And why was that?</p> <p>22 MR. FALKE: I am going to instruct you</p> <p>23 not to answer based on work product grounds.</p> <p>24 A. I cannot answer on the advice of</p> <p>25 counsel.</p>

18 (Pages 66 to 69)

30(b)(6) Deposition of:  
Katherine Seppa

February 10, 2006

Page 70

1 SEPPA

2 **Q. Other than the bending rigidity test**

3 **that you told me about today, between coated and**

4 **uncoated Fiber Wire, the one before Defendant's**

5 **Exhibit 31, and the one after Defendant's Exhibit**

6 **31, were there any other tests, bending rigidity**

7 **tests between coated and uncoated Fiber Wire?**

8 MR. FALKE: Objection, outside the

9 scope.

10 A. I don't recall. I don't remember.

11 **Q. Did you do, after Defendant's Exhibit**

12 **31, did you do an additional straight tensile test**

13 **between coated and uncoated Fiber Wire?**

14 MR. FALKE: Objection, outside the

15 scope.

16 A. I don't remember.

17 **Q. Other than what you have told me about**

18 **today, did you perform or supervise any other**

19 **tests between coated and uncoated Fiber Wire?**

20 MR. FALKE: Objection, outside the

21 scope.

22 A. I don't remember.

23 MR. SABER: Can I have a moment to

24 check my notes?

25 THE WITNESS: Sure.

Page 71

1 SEPPA

2 MR. SABER: Ms. Seppa, I have no

3 further questions of you today. Thank you

4 very much for coming in, and I apologize we

5 kept you until about 10 minutes to 6.

6 THE WITNESS: Thank you.

7 (Time noted: 5:50 p.m.)

8

9

10 KATHERINE RACHEL SEPPA

11 Subscribed and sworn to

12 before me this day

13 of February, 2006.

14

15

16

17

18

19

20

21

22

23

24

25

Page 72

1 SEPPA

2 EXHIBITS

3 Exhibit No. Marked

4 Exhibit 134 document Bates stamped 389 28

5 through 397

6 Exhibit 135 document Bates stamped DMI1147 33

7 through 1153

8 Exhibit 136 document Bates stamped 36

9 DMI94256 through 257

10 Exhibit 137 document Bates stamped 43

11 DMI15592 through 594

12 Exhibit 138 document Bates stamped 53

13 DMI061623 through 62006

14

15

16

17

18

19

20

21

22

23

24

25

Page 73

1 SEPPA

2 CERTIFICATE

3 I, Mary Reilly Bowman, Notary Public

4 and Certified Shorthand Reporter of the

5 State of New Jersey, do hereby certify that

6 prior to the commencement of the examination

7 KATHERINE RACHEL SEPPA was duly sworn by me

8 to testify the truth, the whole truth and

9 nothing but the truth.

10 I DO FURTHER CERTIFY that the

11 foregoing is a true and accurate transcript

12 of the testimony as taken stenographically

13 by and before me at the time, place and the

14 date hereinbefore set forth.

15 I DO FURTHER CERTIFY that I am neither

16 a relative nor employee nor attorney nor

17 counsel of any of the parties to this

18 action, and that I am neither a relative nor

19 employee of such attorney or counsel, and

20 that I am not financially interested in the

21 action.

22

23

24

25

17 Notary Public of the State of New Jersey

18 My commission expires 6/30/2006

19 C.S.R. License No. 30X100226200

20 Dated: 2/22/06

21

22

23

24

25

19 (Pages 70 to 73)